

Form 1449*	Atty. Docket No.: 00443-1703	09/412,539
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: <del>herein</del> Oct. 1999	Group: Unknown 1624

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
BC	2,086,585	07/01/1937	Taub, et al.	260	127	
BC	2,087,132	07/13/1937	Taub, et al.	260	127	
BC	2,108,765	02/15/1938	Domagk	167	30	
BC	2,209,383	07/30/1940	Bock	8	116	
BC	2,439,969	04/20/1948	Fourneau	260	338	
BC	2,445,393	07/20/1948	Fourneau	260	338	
BC	2,513,747	07/04/1950	Sallman, et al.	260	338	
BC	2,606,909	08/12/1952	Blicke	260	338	
BC	2,689,790	09/21/1954	Mowry, et al.	71	2.7	
BC	2,950,253	08/23/1960	Kling, et al.	252	152	
BC	3,054,678	09/18/1962	Michener, et al.	99	150	
BC	3,694,473	09/26/1972	Eibl, et al.	260	403	
BC	4,093,714	06/06/1978	Tolman, et al.	424	180	
BC	4,096,278	06/20/1978	Queuille	424	329	
BC	4,119,714	10/10/1978	Kny, et al.	424	199	
BC	4,159,988	07/03/1979	Eibl, et al.	260	340	
BC	4,235,877	11/25/1980	Fullerton, W.W.	424	89	06/27/79
BC	4,329,302	05/11/1982	Hanahan, et al.	260	925	
BC	4,426,525	01/17/1984	Hozumi, et al.	546	22	
BC	4,444,766	04/24/1984	Bosies, et al.	425	211	
BC	4,471,113	09/11/1984	MacCoss	536	29	
BC	4,540,521	09/10/1985	Garst, et al.	260	459	
BC	4,619,917	10/28/1986	Lee, et al.	514	77	
BC	4,661,509	04/27/1987	Gordon, et al.	514	397	
BC	4,816,450	03/28/1989	Bell, et al.	514	25	
BC	4,826,823	05/02/1989	Cook, et al.	514	46	
BC	4,835,263	05/30/1989	Nguyen, et al.	536	27	
BC	4,837,023	06/06/1989	Eibl	424	439	
BC	4,841,039	06/20/1989	Chu, et al.	536	29	
BC	4,880,782	11/14/1989	Eckstein, et al.	514	45	
BC	5,034,394	07/23/1991	Daluge, S.M.	514	261	12/22/89
BC	5,138,045	08/11/1992	Cook, P.D., et al.	536	27	07/27/90

JC625 U.S. PTO  
 09/412539  
 10/05/99

Examiner <i>Brenda Coleman</i>	Date Considered <i>April 18, 2000</i>
-----------------------------------	--

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 00443-1703	09/412,539
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: <del>herein</del> Oct. 1999	Group: Unknown 1624

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
--------------------	-----------------	------	------	-------	----------	----------------------------

## FOREIGN PATENT DOCUMENTS

	**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	BC	0094586	11/23/1983	European	---	---		
	BC	0109255	05/23/1984	European	---	---		
	BC	0142333	06/19/1985	European	---	---		
	BC	0145303	06/26/1985	European	---	---		
	BC	0146258	05/22/1985	European	---	---		
***	BC	0252310	06/06/1987	European	---	---		
	BC	0310109	04/05/1989	European	---	---		
	BC	0335396	02/23/1989	European	---	---		
	BC	0348859	01/03/1990	European	---	---		
***	BC	0416401	08/25/1990	European	---	---		
	BC	0434450	12/21/1990	European	---	---		
	BC	0506704	07/11/1991	European	---	---		
	BC	0632048	06/23/1994	European	---	---		
***	BC	1029319	01/31/1989	Japan	---	---		
***	BC	1561630	03/28/1969	France	---	---		
***	BC	3726945A1	10/04/1989	Germany	---	---		
***	BC	3934820A1	04/25/1991	Germany	C07F	9/09		
	BC	4010228A1	10/02/1991	Germany	A61K	31/605		
✓	BC	42-13841	08/05/1967	Japan	---	---		
✓	BC	49-100224	09/21/1974	Japan	---	---		
	BC	90/05736	03/13/1991	PCT	---	---		
	BC	90/15601	12/27/1990	PCT	---	---		
***	BC	91/05558	05/02/1991	PCT	---	---		
	BC	91/09602	07/11/1991	PCT	---	---		
	BC	91/18914	12/12/1991	PCT	---	---		
***	BC	92/03462	03/05/1992	PCT	---	---		
	BC	92/06192	04/16/1992	PCT	C12N	15/11		
	BC	93/08807	05/13/1993	PCT	---	---		
***	BC	93/16091	08/19/1993	PCT	---	---		
***	BC	93/16092	08/19/1993	PCT	---	---		
	BC	93/17020	09/02/1993	PCT	---	---		
✓	BC	93/21191	10/28/1993	PCT	C07F	9/10		

Examiner <u>Brenda Coleman</u>	Date Considered <u>April 18, 2000</u>
--------------------------------	---------------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*\*\* structures only

Form 1449*	Atty. Docket No.: <u>00443-1703</u>	<u>09/412,539</u>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: <u>August 7, 1999</u> <del>August 7, 1999</del> <sup>Oct. 1999</sup>	Group: <u>Unknown</u> <sup>1624</sup>

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
-----------------------	-----------------	------	------	-------	----------	-------------------------------

## OTHER DOCUMENTS

\*\*Examiner Initial (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	Aggarwal, "Synthesis and Biological Evaluation of Prodrugs of Zidovudine", <u>J. Med. Chem.</u> , 33, 1505-10 (1990),
BC	Boldanova, et al., "Protective effect of Phosphatidylcholine-containing Liposomes in Experimental Toxic Hepatitis", <u>Vopr. Med. Khim.</u> , 32, no. 3 (1986) <u>Chemical Abstracts</u> , 105, p. 67, Abstract No. 35587k (1986),
✓ BC	Bosies, et al., "Chemical Abstracts", <u>115CA:72142p</u> 1991,
BC	Chen, "Design and Synthesis of Novel Nucleoside Analogs as Potential Antiviral Agents", <u>Abstract American Assoc. of Pharmaceutical Scientists</u> , Orlando Fl., (1993),
BC	Crumpton, "Novel Lipid Analogs with Cytostatic and Cytocidal Activity", <u>Submitted to Anticancer Res.</u> , Vol. 8, No. 6, pp. 1361-1366 (Nov. - Dec. 1988),
BC	Daniel, "Alkyl-Linked Diglycerides Inhibit Protein Kinase C Activation by Diacylglycerols", <u>Biochemical &amp; Biophysical Res. Comm.</u> , 151, 291-97 (Feb. 29, 1988),
BC	Diétzfelbinger, "Cytotoxic and Purgine Effects of ET-18-OCH <sub>3</sub> in Human Malignant Lymphoid Cell Lines in Vitro", <u>Abstract 2472, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990),
BC	Fields, "Human Immunodeficiency Virus Induces Phosphorylation of its Cell Surface Receptor", <u>Nature</u> , 333, 278-80 (19 May 1988),
BC	Harada, "Infection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay", <u>Science</u> , 229, 563- <del>566</del> <sup>566</sup> (9 Aug. 1985),
BC	Himmelmann, "Studies on the Cross Resistance Pattern of Membrane-Toxic Lipids in Vitro", <u>Abstract 2448, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990),

Examiner <u>Brenda Coleman</u>	Date Considered <u>April 18, 2000</u>
--------------------------------	---------------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 00443-1703	09/412,539
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: August 7, 1995 <sup>Oct. 1999</sup> <del>here with</del>	Group: Unknown <sup>1634</sup>

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

BC	Hsu, L., et al., "Synthesis of Anti-Restricted Pyrimidine Acyclic Nucleosides", <u>Journal of Organic Chemistry</u> , Vol. 57, No. 12, pp. 3354-3358, (1992),
BC	Kasnar, B., et al., "Synthesis of 2',3'-Dideoxy- and 3'-Azido-2',3'-Dideoxy-Pyridazine Nucleosides as Potential Antiviral Agents", <u>Nucleosides &amp; Nucleotides</u> , 13(1-3), pp. 459-479, (1994),
BC	Korba, "Use of a Standardized Cell Culture Assay to Assess Activities of Nucleoside Analogs Against Hepatitis B Virus Replication", <u>Antiviral Res.</u> , 19, 55-70 (1992),
BC	Krugner-higby, L., et al., "Membrane-Interactive Phospholipids Inhibit HIV Type 1-Induced Cell Fusion and Surface gp160/gp120 Binding to Monoclonal Antibody", <u>AIDS Research and Human Retroviruses</u> , 11, 705-712, (1995)
BC	Krugner-higby, et al., "Novel Membrane Interactive Ether Lipid Analogs Inhibit HIV-1 Glycoprotein Interaction with CD4+ Cells", <u>Abstract from 32nd Interscience Conf on Antimicrobial Agents and Chemotherapy</u> , Anaheim, 164, (11-14 Oct. 1992),
BC	Kucera, L.S., et al., "Activity of Triciribine and Triciribine-5'-Monophosphate Against Human Immunodeficiency Virus Types 1 and 2", <u>Aids Research and Human Retroviruses</u> , Vol. 9, No. 4, pp. 307-314, (1993),
BC	Kucera, "Effect of Membrane-Active Ether Lipid (EL) Analogues on Human Immunodeficiency Virus Production Measured by Plaque Assay", <u>Annals of the New York Acad. of Sciences</u> , 546-548 (26 Dec. 1990),
BC	Kucera, "Inhibition of HIV-1 Plaque Formation by a Novel Class of Membrane-Active Ether Lipid Analogs", <u>International Conference on AIDS</u> , Abstract No. W.C.O.21, June 4-9, 1989, p. 528.,
BC	Kucera, "Inhibition of Human Immunodeficiency Virus-1 (HIV-1) by Novel Membrane Interactive Ether Lipids", <u>Abstract No. 2470, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990),

Examiner <u>Brenda Coleman</u>	Date Considered <u>April 18, 2000</u>
--------------------------------	---------------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 00 443 - 1743	09/412,539
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: herewith Oct. 1999	Group: Unknown 1624

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

BC	Kucera, L., et al., "Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Medicated Cell Fusion by Synthetic Phospholipid Analogs", <u>Antiviral Research</u> (1995),
BC	Kucera, "Investigations on Membrane Active Ether Lipid Analogs that Alter Functional Expression of HIV-1 Induces Glycoproteins and Inhibit Pathogenesis", <u>Abstract, Innovations in Therapy of Human Viral Diseases, Symposium, Research Triangle Park, 16, (6-9 Dec. 1992),</u>
BC	Kucera, L., et al., "Novel Ether Lipid Analogs of Platelet Activating Factor with Anti-Hepatitis B Virus Activity", <u>Abstract, ICAAC Orlando, (1994),</u>
BC	Kucera, "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation", <u>AIDS Research and Human Retroviruses, 6, 491-501 (1990),</u>
	Kuman, et al., "Chemical Abstract", <u>117CA 124476; (1992)</u>
BC	Kumar, R., et al., "Equal Inhibition of HIV Replication by Stereoisomers of Phosphatidyl-Azidothymidine - Lack of Stereospecificity of Lysosomal Phospholipase A1", <u>J. Biol. Chem., 267, 20288-20292, (1992)</u>
BC	Marasco, Jr., "The Synthesis and Biological Activity of Novel Alkylglycerol Derivatives as Inhibitors of Protein Kinase C Activity, Neoplastic Cell Growth and HIV-1 Infectivity", <u>Dissertation for Ph.D., Univ. of No. Carolina, Chapel Hill 1990,</u>
BC	Marasco, et al., "Synthesis and Biological Activity of Novel Quaternary Ammonium Derivatives of Alkylglycerols as Potent Inhibitors of Protein Kinase C", <u>Jour. of Med. Chem., 33, No. 3, pp. 985-992 (March 1990),</u>
BC	Marasco, "The Synthesis, Biological Evaluation, and Structure Activity of Amido Phosphocholines and Related Analogs as Anti-HIV-1 Agents", <u>6th Conf. on AIDS, San Francisco, Abstract, (20-24 June 1990),</u>
BC	Marasco, et al., "The Synthesis and Biological Testing of Alkyl Glycerols as Potential Inhibitors of Protein Kinase C", <u>American Assoc. of Pharmaceutical Scientists Abstract, Orlando Fl., (1993),</u>

Examiner <i>Brenda Coleman</i>	Date Considered <i>April 18, 2000</i>
-----------------------------------	--

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: <u>00443-1703</u>	<u>09/412,539</u>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: <u>here with Oct. 1999</u>	Group: <u>Unknown</u> <sup>1624</sup>

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

BC	Marx, "Synthesis and Evaluation of Neoplastic Cell Growth Inhibition of 1-N-Alkylamide Analogues of Glycero-3-phosphocholine", <u>J. Med. Chem.</u> , 31, 858-863 (3-28-88),
BC	Meyer, K.L., et al., "In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel Anti-HIV Agents", <u>J. Med. Chem.</u> , 34, 1377-1383, (1991)
BC	Meyer, "Synthesis and Evaluation of Anti-HIV-1 Ether Lipids", <u>AAPS Meeting, Atlanta Abstract N. MN-510, p. S-41, (22-25 Oct. 1989),</u>
	<del>Miller, R.H., et al., "Common Evolutionary Origin of Hepatitis B Virus and Retroviruses", <u>Proc. Natl. Acad. Sci. USA</u>, 83, pp. 2531-2535, (1986)</del>
BC	Mitsuya, "Strategies for Antiviral Therapy in AIDS", <u>Nature</u> , 325, 773-78 (1987),
BC	Modest, "Antineoplastic and Antiviral Properties of Ether Lipid Analogs", <u>15th Intl Cancer Congress, Abstract (16-22 Aug 1990),</u>
BC	Modest, "Combination Chemotherapy Studies with Antitumor and Antiviral Ether Lipid Analogs", <u>Abstract 2471, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 Abstract 2471 (March 1990),
BC	Modest, E., et al., "Comparison of Cell Kill Induced by Two Ether Lipids in Combination with Hyperthermia", <u>Proceedings of the American Association for Cancer Research; Preclinical Pharmacology Experimental Therapeutics, Vol. 31, pp. 416, Abstract 2467, (March 1990),</u>
BC	Modest, "Pharmacological Effects and Anticancer Activity of New Ether Phospholipid Analogs", <u>The Pharmacological Effect of Lipids. III: The Role of Lipids in Carcinogenesis and Therapy, (IN PRESS), pp. 330-337 (1989),</u>
BC	Morrey, "Effects of Zidovudine on Friend Virus Complex Infection in Frv-3r/s Genotype-Containing Mice Used as a Model for HIV Infection", <u>J. of Acquired Immune Deficiency Syndromes</u> , 3, 500-10 (1990),

Examiner <u>Brenda Coleman</u>	Date Considered <u>April 18, 2000</u>
--------------------------------	---------------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 00443-1703	09/412,539
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: herewith Oct. 1999	Group: Unknown 1624

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

BC	Morris-natschke, "Synthesis of Sulfur Analogues of Alkyl Lysophospholipid and Neoplastic Cell Growth Inhibitory Properties", <u>J. of Med. Chem.</u> , 29, 2114-17 (1986),
BC	Nara, "Simple, Rapid, Quantitative, Syncytium-Forming Microassay for the Detection of Human Immunodeficiency Virus Neutralizing Antibody", <u>Aids Res. and Human Retroviruses</u> , 3, 283-302 (1987),
BC	Nosedá, "In Vitro Antiproliferative Activity of Combinations of Ether Lipid Analogues and DNA-interactive Agents Against Human Tumor Cells", <u>Journal of Cancer Research</u> , 48, 1788-1791 (April 1988),
BC	Nosedá, "Neoplastic Cell Inhibition with New Ether Lipid Analogs", <u>Lipids</u> , 22, 878-883 (Nov. 1987),
BC	Ostertag, "Induction of Endogenous Virus and of Thymidine Kinase by Bromodeoxyuridine in Cell Cultures Transformed by Friend Virus", <u>Proc. Nat. Acad. Sci. USA</u> , 71, 4980-85 (Dec. 1974),
	<del>Pacheco, "Mechanisms of Toxicity of Hepsulfam in Human Tumor Cell Lines", Abstract 2446, Proceedings of the American Assoc. for Cancer Res., 31, 416 (March 1990),</del>
BC	Piantadosi, "Synthesis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity", <u>J. Med. Chem.</u> , 34, 1408-14 (1991),
	<del>Pidgeon, et al., "Chemical Abstract", 120CA69591g, (1994)</del>
BC	Sarin, et al., "Effects of a Novel Compound (AL 721) on HTLV-III Infectivity in Vitro", <u>New England J. of Med.</u> , 313, 1289-90 (Nov. 14, 1985),
	<del>Seclero, et al., "Chemical Abstract", 117CA124476p, (1992)</del>
	<del>Small, "Characterization of Cells Sensitive and Resistant to BT 18 OCH3", Abstract 2447, Proceedings of the American Assoc. for Cancer Res., 31, 416 (March 1990),</del>
	<del>Sumamoto, et al., "Chemical Abstract" 117CA68365n, (1992)</del>

Examiner <u>Brenda Coleman</u>	Date Considered <u>April 18, 2000</u>
--------------------------------	---------------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 00443-1703	09/412,539
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Louis S. Kucera et al.	
	Filing Date: herewith Oct. 1999	Group: <del>Unknown</del> 1634

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

BC	Swayze, E.E., et al., "Synthesis of 1-(2-Aminopropyl) Benzimidazoles, Structurally Related to the Tibo Derivative R82150, With Activity Against Human Immunodeficiency Virus", <u>Bioorganic &amp; Medical Chemistry Letters</u> , Vol. 3, No. 4, pp. 543-546, (1993),
BC	Thompson, J., et al., "Phospholipid Analog Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Mediated Cell Fusion", <u>Abstracts of the 2nd National Conference on Human Retroviruses</u> , Session 18, (1995),
BC	Tiollais, P., et al., "Hepatitis B. Virus", <u>Scientific American</u> , 116-123, (April 1992)
BC	Van Wijk, G.M., et al., "Spontaneous and Protein-Mediated Intermembrance Transfer of the Antiretroviral Liponucleotide 3'-Deoxythymidine Diphosphate Diglyceride", <u>Biochem</u> , 31, 5912-5917, (1992)
BC	Yanagawa, "Spontaneous Formation of Superhelical Strands", <u>J. Am. Chem. Soc.</u> , 111, 4567-70 (1989),
BC	Yarchoan, "Therapeutic Strategies in the Treatment of AIDS", <u>Annual Reports in Medicinal Chemistry</u> , 253-263 (1988),

Examiner Brenda Coleman	Date Considered April 18, 2000
----------------------------	-----------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.